Epidemiology Of Cerebral Amyloid Angiopathy: A Single Center Experience (P1.047)

OBJECTIVE: To describe the demographics, risk factors, comorbidities and outcomes of patients with cerebral amyloid angiopathy (CAA) treated at the University of Virginia Medical Center over a 10-year period. BACKGROUND: CAA is a microangiopathy resulting from deposition of Abeta amyloid in cortical and leptomeningeal blood vessels. Clinical presentations are varied and often require tertiary level care. METHODS: We utilized the institutional Clinical Data Repository that consists of clinical and administrative patient information for over 1,000,000 patients. We identified 7161 patients with ICD9 codes representing subarachnoid hemorrhage and intracerebral hemorrhage (ICH) who received care either in the outpatient or inpatient setting over a 10-year period from January 2004-July 2014. Radiological reports of these patients were screened for key words CAA, microhemorrhages or microbleeds and demographics; we also recorded comorbidities and outcome data for those with CAA. RESULTS: We identified 133 patients with CAA of which 51.1[percnt] were men and 66.9[percnt] were between ages 65-84. One third were residents of central Virginia and 75.2[percnt] had Medicare. Inpatient admissions (78[percnt]) were common with 57[percnt] admitted to Neurosurgery and 39[percnt] to the Neuro ICU. Of those admitted, the majority presented to our emergency department (49 [percnt]). Hypertension (82.7[percnt]), cardiac arrhythmias (73.7[percnt])and depression (39.1[percnt]) were significant comorbidities. Average length of stay was 7.89 days with 2.1 days of average ICU stay. Ten patients died, 6 within 31-90 days from last visit. Readmission rates were low with only 7.5[percnt] readmitted within 30 days. CONCLUSIONS: CAA patients who received care at our hospital were older, hypertensive, Medicare beneficiaries from central Virginia. Death rates and readmission rates were low; cause of death was malignant ICH. Further research is ongoing to identify specific radiologic and clinical characteristics of disease in these patients. Disclosure: Dr. Mehndiratta has nothing to disclose. Dr. Chee has nothing to disclose. Dr. Worrall has received personal compensation in an editorial capacity for Neurology. Dr. Worrall has received royalty payments from Merritt9s Neurology.